Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Reverse transcriptase-dependent pyrophosphorolysis is a biochemical reaction catalyzed by reverse transcriptases (RTs), in which the enzyme removes nucleotides from the 3′ end of a DNA or RNA primer in the presence of inorganic pyrophosphate (PPi). This process is essentially the reverse of nucleotide polymerization: instead of adding nucleotides to a growing chain, RT uses PPi to cleave off terminal nucleotides, generating deoxynucleoside triphosphates (dNTPs) as products. In retroviruses like HIV, this activity enables excision of chain terminators introduced by certain antiretroviral drugs, contributing to drug resistance. Efficient pyrophosphorolysis typically occurs when there are more than 14 base pairs in the primer-template region.
Removal of terminal nucleotide(s) via attack on phosphodiester bond using PPi
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Reverse transcriptase-dependent pyrophosphorolysis.